ライフサイエンスコーパス: myogenic cell

1 ts both proliferation and differentiation of myogenic cells.

2 ed Bax translocation and cell death in mouse myogenic cells.

3 ive better under oxidative stress than CD56+ myogenic cells.

4 ion of miR-206 during differentiation of rat myogenic cells.

5 er and repressed FGFR1 gene transcription in myogenic cells.

6 of differentiating into both angiogenic and myogenic cells.

7 entiation of these cells into angiogenic and myogenic cells.

8 sitive satellite cells and other later stage myogenic cells.

9 initial activation of XmyoD transcription in myogenic cells.

10 ly morphological differentiation of cultured myogenic cells.

11 hibition in mouse myoblasts but not in avian myogenic cells.

12 e correction via homologous recombination in myogenic cells.

13 s from the chicken fetus for the presence of myogenic cells.

14 unction to actively assemble and maintain in myogenic cells.

15 populations that can self-renew and generate myogenic cells.

16 ter day 14.5, the promoter becomes active in myogenic cells.

17 e withdrawal and differentiation of skeletal myogenic cells.

18 nts the adhesive and fusogenic properties of myogenic cells.

19 ng that neurons promote the proliferation of myogenic cells.

20 st in part by enhancing the proliferation of myogenic cells.

21 ell-cell interactions between epithelial and myogenic cells.

22 athy affects not only muscle fibres but also myogenic cells.

23 in connective tissue fibroblasts but not in myogenic cells.

24 ized in the nucleoli in both control and DMD myogenic cells.

25 d mesenchymal cells surrounding soft palatal myogenic cells.

26 ntiation and retrospective identification of myogenic cells.

27 muscle tissues ('myobundles') using primary myogenic cells.

28 PTPRQ in non-myogenic cells and MYF5/MYF6 in myogenic cells.

29 were also seen in PTPRQ mRNA-expressing non-myogenic cells.

30 and are critical for differentiation of the myogenic cells.

31 genes and glucose metabolism in mouse C2C12 myogenic cells.

32 muscle eRMS arises from Hh/Gli quiescent non-myogenic cells.

33 d during differentiation and fusion of human myogenic cells.

34 arise from the uncontrolled proliferation of myogenic cells.

35 m myotubes without requiring co-culture with myogenic cells.

36 aling negatively regulates MEF2D function in myogenic cells.

37 X2 expression was lost in the differentiated myogenic cells.

38 s one route to obtain highly desirable human myogenic cells.

39 liferation and reduced apoptosis in cultured myogenic cells.

40 ite cells and are induced in quiescent C2C12 myogenic cells after ectopic expression of either Pax3 o

41 a plays an important role in the survival of myogenic cells after ischemia/reperfusion injury.

42 for a paradigm in which ICAM-1 expressed by myogenic cells after muscle injury augments their adhesi

43 essed by PAX3/FOXO1A or PAX7/FOXO1A in C2C12 myogenic cells again as seen with Pax3/7DN.

44 these two stress proteins is able to protect myogenic cells against ischemia/reperfusion injury.

45 unmethylated at all the CpG sites tested in myogenic cells and a subpopulation of somite cells.

46 ast some ARMSs and the PAX3-FOXO1-expressing myogenic cells and demonstrate that fusion RNA profiling

47 e partially reprogrammed from differentiated myogenic cells and display a pluripotent-like state.

48 ted exclusively in regions that give rise to myogenic cells and dorsal spinal cord components reveali

49 g to isolate transcripts that are present in myogenic cells and in the embryo prior to MRF expression

50 Previous studies have shown that in rodent myogenic cells and in the hearts of transgenic mice in w

51 is transcribed from an intergenic region of myogenic cells and its expression is upregulated during

52 in expression in a much larger collection of myogenic cells and muscle biopsies derived from biceps a

53 uantity is strongly reduced in the patients' myogenic cells and muscle biopsies.

54 ected in FSHD, but not in unaffected control myogenic cells and muscle tissue.

55 e DUX4-fl mRNA and protein were expressed in myogenic cells and muscle tissues derived from FSHD affe

56 s that upregulate expression of PTPRQ in non-myogenic cells and MYF5/MYF6 in myogenic cells.

57 ed fibro/adipogenic progenitors, can support myogenic cells and remodel the extracellular matrix.

58 both the number of terminally differentiated myogenic cells and the intricate slow/fast patterning of

59 The communication between myogenic cells and their surrounding connective tissues

60 perturb localization of Golgi components in myogenic cells, and myofibrillogenesis is normal.

61 When mouse myogenic cells are implanted at the growing tip of early

62 remain distal to endogenous differentiating myogenic cells are more likely to remain undifferentiate

63 -PCR and cell culture analyses indicate that myogenic cells are present in the embryo before somite f

64 ICAM-1-ICAM-1 interactions was restricted to myogenic cells, as forced expression of ICAM-1 by fibrob

65 Treatments that supplement myogenic cells at the same time as co-delivering either

66 S1PR3 levels were high in quiescent myogenic cells before falling during entry into cell cyc

67 w that MIBP is abundantly expressed by C2C12 myogenic cells before fusion, and the expression of MIBP

68 tion at key developmental stages in Emd null myogenic cells, both in vivo and in vitro.

69 tion of human non-muscle cells directly into myogenic cells by forced expression of MyoD represents o

70 Cultured myogenic cells (C(2)C(12)) expressed beta-amyloid-42 (Ab

71 erefore to act as universal mediators of the myogenic cell-cell fusion mechanism underlying formation

72 Here, we show that in mouse muscle and myogenic cells, compensatory regulation of the histone d

73 tory-induced activation of Ccr2 signaling in myogenic cells contributes to aged muscle regenerative d

74 Myogenic cells cotransduced with RCAS(A)-Raf BXB and RCA

75 ies suggest that elevating MBNL3 activity in myogenic cells could lead to muscle degeneration disorde

76 These vectors are able to transduce myogenic cell cultures and express dystrophin in myotube

77 o the expression of muscle-specific genes in myogenic cell cultures.

78 ild-type (WT) littermates, and the number of myogenic cells decreases with age.

79 rrecting oligomer was chosen to treat forced-myogenic cells, derived from fibroblasts from nine patie

80 r, we provide evidence that Cripto modulates myogenic cell determination and promotes proliferation b

81 es demonstrate that limb embryonic and fetal myogenic cells develop from distinct, but related progen

82 lar mechanisms of relaxin in regulating both myogenic cell differentiation and muscle healing process

83 This novel perspective on myogenic cell differentiation revealed previously unreco

84 play multiple functions, including promoting myogenic cell differentiation, cytoskeletal rearrangemen

85 n of Six1 specifically in adult SCs impaired myogenic cell differentiation, impaired myofiber repair

86 f the HDAC6-dysferlin protein complex during myogenic cell differentiation.

87 n originate from aberrant development of non-myogenic cells driven by P3F.

88 ed from mouse fibroblasts, hematopoietic and myogenic cells exhibit distinct transcriptional and epig

89 Myogenic cell expression of ICAM-1 contributed to the re

90 tch signaling pathways are also essential to myogenic cell fate decisions during development and tiss

91 f6 signaling cascade plays a crucial role in myogenic cell fate determination and lineage progression

92 f Notch activity is crucial for specifying a myogenic cell fate only in asymmetric lineages.

93 ifying regulator of myogenesis that controls myogenic cell fate transitions during terminal different

94 balance and promotes the endothelial versus myogenic cell fate, before migration to the limb, in mul

95 reprogramming of muscle stem cells modulates myogenic cell fate.

96 s ligand Serrate apportions myogenic and non-myogenic cell fates within the early Xenopus heart field

97 Satellite cells are myogenic cells found between the basal lamina and the sa

98 cle regeneration, and satellite cell-derived myogenic cells from EphA7(-/-) mice are delayed in their

99 Furthermore, though myogenic cells from genetically Bcl-2-null mice formed m

100 nd protein expression in muscle biopsies and myogenic cells from genetically unaffected relatives of

101 Here we detail a protocol to derive myogenic cells from human embryonic stem (ES) and induce

102 e analyses of these cells along with primary myogenic cells from several developmental stages.

103 the "In-Out" mechanism whereby migration of myogenic cells from the somites into the limb bud is fol

104 Myogenic cells fused normally in vitro, but lacked well-

105 rganization of nuclei within myofibers after myogenic cell fusion.

106 own to interfere with the differentiation of myogenic cells, genetically interacts with PAX7-FKHR: co

107 p21ras is a potent regulator of myogenic cell growth and differentiation.

108 sue; therefore, an unlimited availability of myogenic cells has applications in regenerative medicine

109 investigate whether embryonic and fetal limb myogenic cells have different genetic requirements we co

110 e long been recognized as the main source of myogenic cells in adult muscle, most of the knowledge ab

111 hanced BrdU incorporation into the nuclei of myogenic cells in both the presence and the absence of n

112 tion and polymerase chain reaction analyses, myogenic cells in the constructs were shown to survive i

113 We hypothesized that the early-appearing myogenic cells in the injured area differentiate into my

114 developmental origin of embryonic and fetal myogenic cells in the limb, we genetically labeled and a

115 aB by impairing the regenerative capacity of myogenic cells in the muscle microenvironment to drive m

116 of-function of Pitx2 decreases the number of myogenic cells in the somite, whereas overexpression inc

117 e independent of Smad4-mediated signaling in myogenic cells in the tongue.

118 sparing, but very little is known about the myogenic cells in this muscle group.

119 fited from the study of normal and malignant myogenic cells in vitro, facilitating the identification

120 ain whether migration and differentiation of myogenic cells in vivo are directly regulated by such gr

121 uscle injury triggers the differentiation of myogenic cells (including MC13 cells) into fibrotic cell

122 eta1 into skeletal muscle in vivo stimulated myogenic cells, including myofibers, to express TGF-beta

123 he local expression of this growth factor by myogenic cells, including regenerating myofibers, in inj

124 the expression of Wnt4, Wnt9a, and Wnt10a in myogenic cells, indicating that inhibition occurred thro

125 Expression of SRF-N, the 32-kDa fragment, in myogenic cells inhibited the transcriptional activity of

126 nopathy, we investigated in vitro macrophage-myogenic cell interactions and found that Dysf-deficient

127 t the amount of muscle formed from implanted myogenic cells is greatly augmented by prior irradiation

128 uble mutant, whereas excessive production of myogenic cells is observed in the trunk.

129 In the myogenic cell line C2, we have found that Myf5 expressio

130 isms of IGF action in muscle, we developed a myogenic cell line that overexpresses IGF-binding protei

131 During differentiation of the myogenic cell line, C2C12, muscle-specific MAP4 transcri

132 In this investigation we use a "dyspedic" myogenic cell line, which does not express any ryanodine

133 s prepared from myotubes produced by a mouse myogenic cell line.

134 acterized in vitro using the mammalian C2C12 myogenic cell line.

135 ased during the differentiation of the C2C12 myogenic cell line.

136 D and Myf-5 are critical to establishing the myogenic cell lineage and producing committed, undiffere

137 Whereas ablation of the myogenic cell lineage facilitated adipogenic differentia

138 uscle satellite cells as a model and through myogenic cell lineage-specific NICD(OE) (overexpression

139 tinction between periocular myogenic and non-myogenic cell lineages according to their mutually exclu

140 e that previous support for Myf5-independent myogenic cell lineages was confounded by inefficiencies

141 p38 prevents the differentiation program in myogenic cell lines and human primary myocytes.

142 erences for outgrowth on membranes of clonal myogenic cell lines derived from specific rostral and ca

143 A variety of cell types, including myogenic cell lines, adult skeletal myoblasts, immoratal

144 In myogenic cell lines, phosphorylation of p38beta residue

145 l expression caused aberrant localization of myogenic cells marked with alpha-actin promoter-driven e

146 We have observed that the origin of the myogenic cells may influence their survival in the injec

147 At the forelimb level, endothelial and myogenic cells migrate from adjacent somites into the li

148 Nai;ve myogenic cells migrate from the somites into the develop

149 sed in this abnormal domain, indicating that myogenic cell migration and differentiation are occurrin

150 n de novo FSHD, we have established a clonal myogenic cell model from a mosaic patient.

151 lineage tracers into single identified adult myogenic cells (muscle or noncontractile muscle-derived

152 These results suggest that, at least in myogenic cells, nuclear Tmod may be involved in the diff

153 ese results reveal specific abnormalities in myogenic cell number and behavior associated with SPEG d

154 tudies demonstrate specific abnormalities in myogenic cell number and behavior that may relate to the

155 ivo and exogenous Fgf18 can partially rescue myogenic cell numbers in Osr2(Cre);Tgfbr1(fl/fl) samples

156 lpha2-deficient muscles and cells, including myogenic cells obtained from patients with a clinical di

157 erative capacity, and in vivo engraftment of myogenic cells obtained from severely symptomatic (Mtm1d

158 ation, proliferation, and differentiation of myogenic cells obtained from striated muscle-specific Sp

159 at FP-RMS is not derived from an exclusively myogenic cell of origin.

160 expressed exclusively and transiently in the myogenic cells of the differentiating chicken heart was

161 pCMF1 is transiently expressed within the myogenic cells of the primitive heart tube from stages 9

162 minantly expressed by macrophages but not by myogenic cells or capillary endothelia cells in injured

163 CCR2 was not detected in myogenic cells or capillary endothelial cells in injured

164 Fetal myogenic cells originating from transgenic mice carrying

165 Myogenic cells overexpressing activated Raf and kinase-d

166 ip between expression and phenotype in human myogenic cells, PAX3-FKHR was introduced into immortaliz

167 dentified in addition to the expected GFP(+) myogenic cells (presumably satellite cells), a second do

168 induction of growth factors and reduction of myogenic cell proliferation and differentiation activiti

169 Myogenic cell proliferation and differentiation are regu

170 regeneration and reveals highly coordinated myogenic cell proliferation and differentiation programs

171 lly controlled transcriptional regulation of myogenic cell proliferation and differentiation via expr

172 is and Fgf10 expression as well as decreased myogenic cell proliferation, reduced cell number and dis

173 thesis that TRIM32 is involved in control of myogenic cells proliferation and differentiation.

174 ulators of fiber type, low levels of Tcf4 in myogenic cells promote both slow and fast myogenesis, th

175 shRNA knockdown of CD82 in myogenic cells reduces myoblast proliferation, suggestin

176 rotein, and enzyme activity in all patients' myogenic cells, regardless of the nature of the mutation

177 Constitutive PKD activation in mouse C2C12 myogenic cells regulated metabolic genes and glucose met

178 G deficiency on the survival and function of myogenic cells remains to be deciphered.

179 We show that myogenic cells secrete Fam3a, and exposure of Stat3-abla

180 blastoma subtype containing muscle elements, myogenic cells share cytogenetic signatures with the pri

181 Under coculture conditions with myogenic cells, some cells within the SP cell population

182 s and their controls however, implying a non-myogenic cell source in muscle biopsies.

183 A wide variety of myogenic cell sources have been used for repair of injur

184 The 10T1/2-MRF4 fibroblast/myogenic cell system was used to address the following i

185 ofibers from HFrD rats gave rise to 20% less myogenic cells than the Ang 1-7-treated rats.

186 Mtm1delta4 muscle contains fewer myogenic cells than wild-type (WT) littermates, and the

187 Myogenic cells that are able both to carry full-length g

188 d differentiation and guides cells to become myogenic cells that form FP-RMS tumors in immunocompromi

189 Pax3 was not expressed by myogenic cells that migrate into the branchial arches de

190 initiate regeneration promptly by activating myogenic cells that proliferate and differentiate into m

191 As myod expression is restricted to myogenic cells, the data show that myogenesis is essenti

192 In contrast to the other two populations of myogenic cells, the transplantation of the long-time pro

193 n response to muscle injury, and the derived myogenic cells then fuse to repair damaged muscle fibers

194 ades in skeletal muscle and the induction of myogenic cells to differentiate into myofibroblastic cel

195 dbrain and branchial arches act on migrating myogenic cells to influence their gene expression and de

196 ization characteristics of these kinesins in myogenic cells to others previously identified in muscle

197 n, perimysial fibroblasts, communicates with myogenic cells to regulate mouse pharyngeal myogenesis.

198 r the first time the susceptibility of human myogenic cells to SINV infection.

199 iding a positive feedback loop that switches myogenic cells to terminal differentiation.

200 We conclude that the vast majority of myogenic cells transit through a MyoD+ state, and that M

201 Myogenic cell transplantation (MT), a potential therapy

202 an be exploited to potentiate the outcome of myogenic cell transplantation into dystrophic muscles.

203 Myogenic cell transplantation survival was decreased whe

204 rentiation was reversible and independent of myogenic cell type.

205 A surprisingly wide range of non-myogenic cell types improves ventricular function, sugge

206 scle-specific gene expression in these three myogenic cell types.

207 d arrow M(264)) by caspase-6 in vitro and in myogenic cells undergoing apoptosis.

208 a-1 expression is upregulated in a subset of myogenic cells upon muscle injury.

209 Transient energy deprivation of H9c2 myogenic cells, used as an in vitro model of myocardial

210 To examine the role of FAK in the fusion of myogenic cells, we examined the expression of FAK and th

211 In mouse myogenic cells, we found that, as in non-muscle cells, B

212 To clarify the origin(s) of adult myogenic cells, we used phenotypic, morphological, and f

213 ofibers in the nonlacerated muscle and these myogenic cells were gradually replaced by myofibroblasti

214 Three populations of myogenic cells were isolated from normal mouse skeletal

215 through embryoid body method and MYF5-GFP(+) myogenic cells were sorted and characterized.

216 Because tumor cells or myogenic cells were used for those studies, it is not cl

217 ficient mouse muscle and primary human MDC1A myogenic cells, which indicates a conserved mechanism of

218 G-deficient skeletal muscles contained fewer myogenic cells, which on further study demonstrated redu

219 Treatment of myogenic cells with pan-HDAC or HDAC6-specific inhibitor

220 bition of PRC2 permits MyoD re-expression in myogenic cells with reduced Spt6.

221 mportant in electromechanical integration of myogenic cells with surrounding re-cipient rat cardiomyo

222 mental relationships between endothelial and myogenic cells within human skeletal muscle.

223 aling (1) blocks terminal differentiation of myogenic cells within the somite and (2) sustains myobla

224 ed for the normal mediolateral patterning of myogenic cells within the somite.